UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/019,385	04/25/2002	Silvia Buervenich	1103326-0677	1420	
	7470 7590 08/18/2008 WHITE & CASE LLP			EXAMINER	
PATENT DEPA	ARTMENT	,	QIAN, CELINE X		
1155 AVENUE OF THE AMERICAS NEW YORK, NY 10036			ART UNIT	PAPER NUMBER	
			1636		
			MAIL DATE	DELIVERY MODE	
			08/18/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/019,385	BUERVENICH ET AL.
Office Action Summary	Examiner	Art Unit
	CELINE X. QIAN	1636
The MAILING DATE of this communication appeariod for Reply	opears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perio - Failure to reply within the set or extended period for reply will, by statu. Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be tired will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) ☐ Responsive to communication(s) filed on 15 2a) ☐ This action is FINAL . 2b) ☐ Th 3) ☐ Since this application is in condition for allow closed in accordance with the practice under	is action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-6,8-20 and 24-37 is/are pending in 4a) Of the above claim(s) 12-20 and 24-37 is/s 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-6,8-11 and 32-34 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/s Application Papers	are withdrawn from consideration.	
9) The specification is objected to by the Examir 10) The drawing(s) filed on 16 March 2006 is/are. Applicant may not request that any objection to the Replacement drawing sheet(s) including the corre	: a)⊠ accepted or b)⊡ objected t e drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).
11)☐ The oath or declaration is objected to by the E	Examiner. Note the attached Office	Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority document 2. ☐ Certified copies of the priority document 3. ☐ Copies of the certified copies of the priority document application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicat fority documents have been receive au (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate

DETAILED ACTION

Claims 1-6, 8-20, 24-37 are pending in the application. Claims 12-20, 24-31 and 25-37 are withdrawn from consideration for being directed to non-elected subject matter. Claims 1-6, 8-11 and 32-34 are currently under examination.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/15/08 has been entered.

Response to Amendment

The rejection of claims 32 and 33 under 35 U.S.C.112 2nd paragraph has been withdrawn in light of the amendment.

The rejection of claim 33 under 35 U.S.C.101 has been withdrawn in light of the amendment.

The rejection of claims 1-6, 8-11, 32-34 under 35 U.S.C.112 1st paragraph is discussed below.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Application/Control Number: 10/019,385 Page 3

Art Unit: 1636

Claims 1-6, 8-11, 32-34 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

The amendment in claim 1 now recites the limitation of "and wherein the mutation(s) in the gene, fragment or variant is/are linked to schizophrenia and/or manic depressive illness."

While the specification teaches the mutation in the Nurr1 gene is linked to schizophrenia and/or manic depressive illness," it does not describe any functional fragment or variant that comprises the mutation which also linked to schizophrenia and/manic depressive illness. The cited paragraphs from the specification, namely, line 22 page 6 through page 7, line 9, describe the possible link of the Nurr1 gene and the neuro-psychiatric disorder, and the passage from page 5, line 21 through page 6, line 20, describes fragments of Nurr1. However, the specification does not teach the fragments described from page 5, line 21 through page 6, line 20 are linked to neuron-psychiatric disorder. In other words, the paragraphs describe two concepts separately. Since this newly presented limitation is not described in the specification as filed, they constitute new matter.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 32 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over the sequence having the accession number NM_006186 which is disclosed by Mages et al (Molecular Endocrinology, 1994. Vol.8: pages 1583-1591).

The sequence presented in NM_006168 was disclosed in Mages et al. (see page 1884, figure 1B). The cDNA of human NOT/Nurr1 would hybridize to the Nurr1 gene, portions of Nurr1 gene. It would have been obvious to one of ordinary skill in the art to place the cDNA in a vector and transfer the vector to a cell for expression of the protein product. Therefore, the claimed invention would have been obvious to an ordinary artisan at the time of filing.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CELINE X. QIAN whose telephone number is (571)272-0777. The examiner can normally be reached on 10-6:30 M-F.

Application/Control Number: 10/019,385 Page 5

Art Unit: 1636

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joe Woitach Ph.D. can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Celine X Qian Ph.D./ Primary Examiner, Art Unit 1636